GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Instil Bio Inc (NAS:TIL) » Definitions » Tax Expense

TIL (Instil Bio) Tax Expense : $0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Instil Bio Tax Expense?

Instil Bio's tax expense for the months ended in Sep. 2024 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.


Instil Bio Tax Expense Historical Data

The historical data trend for Instil Bio's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instil Bio Tax Expense Chart

Instil Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
- 0.15 0.04 -2.07 -

Instil Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Instil Bio Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Instil Bio  (NAS:TIL) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Instil Bio Tax Expense Related Terms

Thank you for viewing the detailed overview of Instil Bio's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Instil Bio Business Description

Traded in Other Exchanges
N/A
Address
3963 Maple Avenue, Suite 350, Dallas, TX, USA, 75219
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FR?, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Executives
Timothy L. Moore officer: Chief Operating Officer C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Sumita Ray officer: Chief Legal and Admin Officer C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Nimish P Shah director 7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Jack Nielsen director, 10 percent owner C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vivo Capital Fund Ix, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Mcgaughy R Kent Jr director 500 CRESCENT COURT, SUITE 250, DALLAS TX 75201
Curative Ventures V Llc 10 percent owner 3963 MAPLE AVENUE, SUITE 390, DALLAS TX 75219
Bronson Crouch director, 10 percent owner, officer: CEO and Chairman C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Vivo Capital Ix, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Sandeep Laumas officer: CFO and CBO 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Neil W Gibson director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Gwendolyn Binder director C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Zachary Roberts officer: Chief Medical Officer C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
George Matcham director C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Vijay Chiruvolu officer: Chief Technical Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037

Instil Bio Headlines

From GuruFocus